T2 Biosystems, Inc. (NASDAQ:TTOO – Get Free Report) was the target of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 624,900 shares, a decline of 28.6% from the November 30th total of 875,200 shares. Based on an average trading volume of 782,300 shares, the short-interest ratio is currently 0.8 days. Currently, 6.7% of the shares of the company are sold short.
Institutional Investors Weigh In On T2 Biosystems
An institutional investor recently bought a new position in T2 Biosystems stock. Armistice Capital LLC acquired a new stake in shares of T2 Biosystems, Inc. (NASDAQ:TTOO – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned approximately 9.49% of T2 Biosystems at the end of the most recent quarter. Institutional investors own 23.18% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on T2 Biosystems in a research report on Saturday. They issued a “sell” rating for the company.
T2 Biosystems Trading Up 3.7 %
T2 Biosystems stock traded up $0.02 during mid-day trading on Friday, hitting $0.43. 795,770 shares of the company traded hands, compared to its average volume of 404,656. T2 Biosystems has a one year low of $0.31 and a one year high of $8.38. The stock has a fifty day moving average price of $0.62 and a 200-day moving average price of $2.64.
T2 Biosystems Company Profile
T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
Featured Articles
- Five stocks we like better than T2 Biosystems
- The Most Important Warren Buffett Stock for Investors: His Own
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- How to Invest in Biotech Stocks
- Top 3 ETFs to Hedge Against Inflation in 2025
- What Are the U.K. Market Holidays? How to Invest and Trade
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.